Back to top
more

Xencor (XNCR)

(Delayed Data from NSDQ)

$23.03 USD

23.03
658,302

+0.57 (2.54%)

Updated May 17, 2024 04:00 PM ET

After-Market: $23.02 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts See a 55% Upside in Xencor (XNCR): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 55.4% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Xencor (XNCR) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Xencor (XNCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top Ranked Momentum Stocks to Buy for October 7th

by Zacks Equity Research

XNCR, ARCB, RRC, and NTR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 7, 2021

Xencor (XNCR) Inks Deal With J&J for B-Cell Malignancy Treatment

by Zacks Equity Research

Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.

Xencor (XNCR) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 242.62% and 296.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 10.9% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

by Zacks Equity Research

Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

by Zacks Equity Research

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze

by Zacks Equity Research

Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

Xencor (XNCR) Loses 12.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Kinjel Shah headshot

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

by Kinjel Shah

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

by Zacks Equity Research

Omeros (OMER) announces initial results from a phase I study of OMS906.

Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review

by Zacks Equity Research

Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.

United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF

by Zacks Equity Research

United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

by Zacks Equity Research

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.

Minerva (NERV) Soars on Promising Schizophrenia Study Data

by Zacks Equity Research

Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 94.81% and 160.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 55.56% and 97.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer

by Zacks Equity Research

Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.

Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal

by Zacks Equity Research

Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of 0.00% and -2.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of -8.93% and 43.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Xencor (XNCR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte, MorphoSys Application for Lymphoma Drug Validated

by Zacks Equity Research

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.